Collaborative group phase III study shows Roche’s Avastin improves survival in patients with mesothelioma - a devastating type of thoracic cancer
Roche announced today phase III results from a collaborative group study that showed that patients with malignant pleural mesothelioma, a rare type of cancer that affects the lining of the lungs, lived significantly longer when treated with Avastin in combination with standard therapy (pemetrexed and cisplatin chemotherapy) compared to standard therapy alone. (Source: Roche Investor Update)
Source: Roche Investor Update - May 30, 2015 Category: Pharmaceuticals Source Type: news

Pharmacists Warn of Ophthalmic Drug ShortagesPharmacists Warn of Ophthalmic Drug Shortages
Compounding pharmacists say new regulations could limit the supply of ophthalmic drugs, such as macular degeneration formulations of bevacizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 29, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Avastin, the first cervical cancer drug for 10 years
Patients will have access via the Cancer Drugs Fund (CDF) until it is considered for routine NHS use. It has been available in England via the CDF since last March pending licensing. (Source: the Mail online | Health)
Source: the Mail online | Health - April 28, 2015 Category: Consumer Health News Source Type: news

EU approves Roche's Avastin plus chemotherapy for women with advanced cervical cancer
Roche announced today that the European Commission (EU) approved Avastin (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Media News)
Source: Roche Media News - April 8, 2015 Category: Pharmaceuticals Source Type: news

EU approves Roche's Avastin plus chemotherapy for women with advanced cervical cancer
Roche announced today that the European Commission (EU) approved Avastin (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Investor Update)
Source: Roche Investor Update - April 8, 2015 Category: Pharmaceuticals Source Type: news

Roche's Avastin plus chemotherapy receives European approval for cervical cancer
Switzerland-based Roche has received approval from the European Commission for its Avastin (bevacizumab) in combination with standard chemotherapy to treat adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 8, 2015 Category: Pharmaceuticals Source Type: news

GMC steps into eye drug row
Regulator says controversy surrounding use of Avastin places doctors in "invidious" position Related items from OnMedicaGPs slam Superdrug home genetics test kitNovartis accused of attempt to derail eye drug trialsParacetamol "does not help back pain or arthritis"Prescribing rights of allied health professionals to be widenedGPs under spotlight in drive to cut antibiotic prescribing (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 7, 2015 Category: UK Health Source Type: news

New Mesothelioma Treatment Options Are Emerging for Patients
Although no definitive cure is in sight, the treatment of malignant pleural mesothelioma has entered a promising, much-anticipated phase that goes beyond the multimodal approach that has been the standard of care at specialty centers for the past several years. There is new hope on the horizon. Thoracic surgeon and renowned mesothelioma specialist Dr. Robert Cameron, along with scientist Raymond Wong, Ph.D., and thoracic and cardia surgeon Dr. Svetlana Kotova, recently detailed the changing face of therapy in a paper they co-authored and published in the Cancer Management Research Journal . "With all the ongoing r...
Source: Asbestos and Mesothelioma News - April 2, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Bevacizumab in Ovarian Cancer Extends Overall SurvivalBevacizumab in Ovarian Cancer Extends Overall Survival
Adding the antiangionic agent to combination chemotherapy shows a clinically meaningful improvement in overall survival compared with standard chemotherapy alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mixed Results for Avastin Plus Chemo in Ovarian Cancer (CME/CE)
(MedPage Today) -- Regimen improves survival but study misses cutoff for statistical significance. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 30, 2015 Category: Hematology Source Type: news

Women with ovarian cancer gain extra months with addition of drug to standard chemotherapy
Overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 28, 2015 Category: Science Source Type: news

Is Bevacizumab Truly a New Standard in Cervical Cancer?Is Bevacizumab Truly a New Standard in Cervical Cancer?
New data on quality of life show 'convincingly' that it is not adversely affected, but does it all add up to a new standard? Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)
Interim Data Demonstrate Statistically Significant Improvement in Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin(R)) TEL AVIV, Israel, March 25, 2015 -- (Healthcare Sales & Marketing Network) -- VBL Therapeutic... Biopharmaceuticals, OncologyVBL Therapeutics, VB-111, glioblastoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 25, 2015 Category: Pharmaceuticals Source Type: news

Avastin Macular Edema and Degeneration Market Analysis & Forecast...
RnRMarketResearch.com adds “Avastin (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023” to its store.(PRWeb March 17, 2015)Read the full story at http://www.prweb.com/releases/avastin-macular-edema/degeneration-market-2023/prweb12588888.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 19, 2015 Category: Pharmaceuticals Source Type: news

A new study for people with Renal Cell Carcinoma (RCC)
This study will explore the effectiveness of the experimental drug known as CRLX101 combined with bevacizumab (Avastin), in patients with metastatic renal cell carcinoma (RCC).03/04/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2015 Category: Cancer & Oncology Source Type: news

Genentech delves into apps to link with breast cancer patients
Over years of cancer drug research, Genentech Inc. has kept a keen watch on patients: how they respond to drugs in a clinical trial, for example, or what patients need in a next-generation drug. Yet even as the South San Francisco-based biotech unit of Swiss drug giant Roche developed some of the best-selling and effective cancer drugs — Avastin and Herceptin among them — it heard from patients that the medications themselves were not enough. Breast cancer patients, in particular, wanted to… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 3, 2015 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

EU recommends Roche’s Avastin plus chemotherapy to treat cervical cancer
The European Union's (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of Avastin (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan in patients who cannot re… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 2, 2015 Category: Pharmaceuticals Source Type: news

ABPI respond to call to allow off-label prescribing of Avastin
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2015 Category: Drugs & Pharmacology Source Type: news

Roche says EU agency recommends Avastin for cervical cancer
ZURICH (Reuters) - Roche said on Friday that European regulators had recommended approval of its drug Avastin in combination with chemotherapy as a treatment for women with an advanced form of cancer of the cervix. (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Roche’s Avastin plus chemotherapy receives positive recommendation from CHMP for EU approval in advanced cervical cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of Avastin® (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Media News)
Source: Roche Media News - February 27, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Avastin plus chemotherapy receives positive recommendation from CHMP for EU approval in advanced cervical cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of Avastin® (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Investor Update)
Source: Roche Investor Update - February 27, 2015 Category: Pharmaceuticals Source Type: news

UK doctors urge use of Roche's Avastin as cheap eye drug
LONDON (Reuters) - British doctors called on Tuesday for Roche's cancer drug Avastin to be made routinely available as a cheap alternative for treating people with a debilitating eye disorder. (Source: Reuters: Health)
Source: Reuters: Health - February 24, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

NHS 'must step in' over Avastin row
Doctors call on health ministers and NHS England to intervene to make a drug called Avastin routinely available to patients with a debilitating eye condition known as wet AMD. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 24, 2015 Category: Consumer Health News Source Type: news

Researcher at Johns Hopkins Helps Lead Discovery on Efficacy and Safety of Eylea, Lucentis and Avastin for Treating Patients with Diabetic Macular Edema - 2/20/15
A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs — Eylea, Avastin and Lucentis — used to treat diabetic macular edema are all effective. (Source: Johns Hopkins Medicine News)
Source: Johns Hopkins Medicine News - February 20, 2015 Category: Research Source Type: news

Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
Lucentis and Avastin perform similarly to Eylea when vision loss is mild, NIH study shows. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 19, 2015 Category: American Health Source Type: news

Johns Hopkins Helps lead discovery on efficacy and safety of 3 drugs for treating DME
(Johns Hopkins Medicine) A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2015 Category: Global & Universal Source Type: news

Anti-VEGF Drugs Boost Vision in Diabetic Eyes (CME/CE)
(MedPage Today) -- Relative effects of intravitreous aflibercept, bevacizumab, and ranibizumab depend on baseline visual acuity. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - February 19, 2015 Category: Urology & Nephrology Source Type: news

Study Compares Drugs for Diabetes-Linked Eye Disease
Eylea has slight advantage over Avastin, Lucentis for people with macular edema, but cost is an issue (Source: WebMD Health)
Source: WebMD Health - February 19, 2015 Category: Consumer Health News Source Type: news

Anti-VEGF Agents Tied to Improved Visual Acuity in Diabetic Macular Edema (FREE)
By Kelly Young Edited by Susan Sadoughi, MD Aflibercept (Eylea), bevacizumab (Avastin), and ranibizumab (Lucentis) all lead to improved vision in patients with diabetic macular edema, although aflibercept may be most effective for those with the worst baseline vision, a New England … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 19, 2015 Category: Primary Care Source Type: news

3 Drugs for an Eye Disease, With Big Price Gaps, Are Found to Be Equals for Many
The three drugs — Eylea, Lucentis and Avastin — are meant to treat a condition known as macular edema, which occurs primarily in patients with diabetes. (Source: NYT Health)
Source: NYT Health - February 19, 2015 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Eyes and Eyesight Roche Holding AG RHHBY Other OTC National Eye Institute Research Eylea (Drug) Regeneron Pharmaceuticals Inc REGN NASDAQ Source Type: news

Study Compares Drugs for Diabetes-Linked Eye Disease
Eylea has slight advantage over Avastin, Lucentis for people with macular edema, but cost is an issue Source: HealthDay Related MedlinePlus Pages: Diabetic Eye Problems, Eye Diseases, Retinal Disorders (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 18, 2015 Category: Consumer Health News Source Type: news

Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the National Institutes of Health. Language English (Source: News from NEI)
Source: News from NEI - February 16, 2015 Category: Opthalmology Authors: Jason Source Type: news

BRVO: Bevacizumab and Ranibizumab Both EffectiveBRVO: Bevacizumab and Ranibizumab Both Effective
Treatment with anti-VEGF therapy results in rapid improvements in anatomy and function in patients with macular edema caused by branch retinal vein occlusion. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 11, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Second Turkish man sentenced for smuggling counterfeit cancer drugs
Today, the U.S. District Court of the Eastern District of Missouri sentenced Sabahhadin Akman, an owner of the Turkish firm Ozay Pharmaceuticals, to 30 months imprisonment and a $150,000 fine for smuggling counterfeit, misbranded and adulterated cancer treatment drugs into the U.S., including multiple shipments of Altuzan, the Turkish version of Avastin. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 23, 2015 Category: American Health Source Type: news

New First-line Option for Advanced Colorectal CancerNew First-line Option for Advanced Colorectal Cancer
In patients with advanced colorectal cancer, the rate of 5-year overall survival was twice as high with FOLFOXIRI plus bevacizumab as with FOLFIRI plus bevacizumab. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 14, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

More Drugs, Better Survival in Metastatic Colon Cancer
(MedPage Today) -- Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 13, 2015 Category: Primary Care Source Type: news

January Cervical Cancer Month: Progress Is Promising
January is Cervical Cancer Month. So it is time to look at what has been accomplished recently in control of this disease. Getting treatment for advanced cervical cancer is challenging. Patients often have pelvic pain, sometimes with blockage of intestines and the urinary tract. Regrettably many patients have fistulas (holes) develop where they leak urine or stool through the skin, vagina or bladder. These are cruel consequences of failed cancer control. About 13,000 women will develop cervical cancer every year, and tragically 4,000 will die of the illness. In 2014, the FDA approved a new treatment for advanced cervical...
Source: Healthy Living - The Huffington Post - January 9, 2015 Category: Consumer Health News Source Type: news

Anger as fund cuts six breast cancer drugs
Avastin is one of six breast cancer drugs deemed to offer either ‘insufficient value for money’ or or have poor cost-benefit scores for breast cancer, and have been banned from use by NHS patients. (Source: the Mail online | Health)
Source: the Mail online | Health - January 8, 2015 Category: Consumer Health News Source Type: news

The Year in Gynecologic Cancer: Bevacizumab and BeyondThe Year in Gynecologic Cancer: Bevacizumab and Beyond
Dr Maurie Markman highlights the most important developments and practice-changing clinical trials of 2014. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Two drugs before surgery help women with triple-negative breast cancer, research shows
A breast cancer specialist and clinical researcher shows that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 15, 2014 Category: Science Source Type: news

Research: Two drugs before surgery help women with triple-negative breast cancer
(Women & Infants Hospital) A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 15, 2014 Category: Global & Universal Source Type: news

Bevacizumab Works in Triple-Negative Breast Cancer SubtypeBevacizumab Works in Triple-Negative Breast Cancer Subtype
New results could reignite interest in the use of bevacizumab in breast cancer, especially in a subtype of triple-negative disease. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Platinum agent combination treatment for triple-negative breast cancer well tolerated in phase II clinical trial
New research shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior treatment for their metastatic disease. The work also included genomic profiling to measure molecular correlates of response. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 9, 2014 Category: Science Source Type: news

Paid to Promote Eye Drug, and Prescribing It Widely
Half of the 20 doctors who received the most money from Genentech to promote its drug Lucentis in 2013 were among the highest users of the drug in 2012, a federal database shows. (Source: NYT Health)
Source: NYT Health - December 8, 2014 Category: Consumer Health News Authors: By KATIE THOMAS and RACHEL ABRAMS Tags: Medicare Lucentis (Drug) Doctors Roche Holding AG RHHBY Other OTC Macular Degeneration Genentech Inc Avastin (Drug) Source Type: news

Navigating the Treatment Landscape
for Advanced-stage Kidney Cancer Mayer N. Fishman, MD, PhD For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices. The physician must weigh how quickly the cancer is spreading, the pattern of that spread, and relative risks from other medical conditions against the patient’s individual treatment goals and medical needs. In many cases of patients with advanced disease, there are therapies that can realistically be used to meet the goals of longer survival, longer time to disease progression, and tumor shrinkage. While choosing a kidney cancer treatment can ...
Source: Kidney Cancer Association - December 3, 2014 Category: Cancer & Oncology Source Type: news

Navigating the Treatment Landscape
for Advanced-stage Kidney Cancer Mayer N. Fishman, MD, PhD For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices. The physician must weigh how quickly the cancer is spreading, the pattern of that spread, and relative risks from other medical conditions against the patient’s individual treatment goals and medical needs. In many cases of patients with advanced disease, there are therapies that can realistically be used to meet the goals of longer survival, longer time to disease progression, and tumor shrinkage. While choosing a kidney cancer treatment can be a...
Source: Kidney Cancer Association - December 3, 2014 Category: Urology & Nephrology Source Type: news

Navigating the Treatment Landscape
for Advanced-stage Kidney CancerMayer N. Fishman, MD, PhDFor the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices. The physician must weigh how quickly the cancer is spreading, the pattern of that spread, and relative risks from other medical conditions against the patient’s individual treatment goals and medical needs. In many cases of patients with advanced disease, there are therapies that can realistically be used to meet the goals of longer survival, longer time to disease progression, and tumor shrinkage. While choosing a kidney cancer treatment can be a com...
Source: Kidney Cancer Association - December 3, 2014 Category: Urology & Nephrology Source Type: news

Bevacizumab for AMD could save UK's NHS £ millions
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2014 Category: Drugs & Pharmacology Source Type: news